Moderna Inc. (MRNA)
Moderna, Inc. (MRNA) Q2 2025 Earnings Call Transcript
Moderna, Inc. (NASDAQ:MRNA ) Q2 2025 Earnings Conference Call August 1, 2025 8:00 AM ET Company Participants James M. Mock - Chief Financial Officer Lavina Talukdar - Senior VP & Head of Investor Relations Stéphane Bancel - CEO & Director Stephen Hoge - President Conference Call Participants Courtney Breen - Sanford C.
Moderna slashes full-year sales outlook, reduces headcount
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares fell almost 9% in early trade as the pharmaceutical giant lowered its full-year guidance and announced a workforce reduction, overshadowing a Q2 earnings beat. The company lowered its 2025 revenue outlook by $300 million to a range of $1.5 billion to $2.2 billion, attributed to shipment timing.
Moderna Stock Drops as Firm Cuts Revenue Outlook on UK Vaccine Deliveries Delay
Shares of Moderna (MRNA) fell sharply Friday after the company lowered the top end of its full-year revenue outlook because of a delay in vaccine deliveries to the UK.
Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates
Moderna (MRNA) came out with a quarterly loss of $2.13 per share versus the Zacks Consensus Estimate of a loss of $2.99. This compares to a loss of $3.33 per share a year ago.
Moderna is laying off 10% of its workforce. Does RFK Jr. have anything to do with it?
Biotech giant Moderna announced it will lay off 10% of its workforce in a move CEO Stéphane Bancel called “a difficult decision but necessary step forward,” in an internal memo sent to employees on July 31.
Moderna quarterly sales beat Street estimates on COVID booster sales, cost cuts
Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by robust Spring COVID booster demand and aggressive cost cuts.
Moderna cuts high end of 2025 revenue outlook on vaccine shipment delay in U.K.
Moderna lowered the high end of its 2025 revenue outlook, citing a delay in vaccine shipments to the U.K. The company lost less than Wall Street analysts were expecting for the second quarter and posted revenue that topped estimates.
More than 800 Moderna employees will lose their jobs this year as costs are slashed
In a note to employees on Thursday, Moderna Inc. said it was laying off about 10% of its global workforce as part of the biotechnology company's plan to cut costs by $1.5 billion over the next couple of years.
Moderna to slash 10% of workforce as biotech cuts costs, Covid shot sales slow
Moderna said it plans to slash roughly 10% of its global workforce by the end of the year, as Covid shot sales continue to dwindle and the company grapples with uncertainty in the vaccine market. In a memo to employees, Moderna CEO Stephane Bancel said the company expects to have fewer than 5,000 workers by the end of the year.
Pandemic darlings Moderna, BioNTech are now on two different paths
Covid-19 vaccine makers Moderna and BioNTech became household names almost overnight. Moderna and BioNTech have spent their Covid vaccine windfalls differently, with Moderna investing in its own mRNA technology and BioNTech pursuing deals to diversify its pipeline.
Curious about Moderna (MRNA) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Evaluate the expected performance of Moderna (MRNA) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?
MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.
